Sales of Remicade jumped 34% to $373 million, while Nasonex sales leapt 24% to $284 million. Revenue from the company's joint venture with Merck & Co. ...
Remicade sales grew 34% to $373 million in the quarter, and Nasonex was up 24% to $284 million. Sales of all of the company's top nine products were up at ...